The Strategic and Scientific Imperative for Prospectively Generated Real-World Evidence

(Moderator) Jeff Trotter, Senior Vice President, Scientific Solutions, Real World Evidence, Worldwide Clinical Trials

Jeff Trotter, Senior Vice President for Worldwide Evidence™, supports clients with the critical transition from clinical development to commercialization. With more than three decades of experience and an MBA from Northwestern University, Jeff brings a pioneering spirit to the evolving real-world evidence research community. As an accomplished speaker and author with over 50 published articles and research papers, he prioritizes personalized client service, practical and strategic guidance based in experience, and candid communications grounded in mutual respect and cultural sensitivity through his role at Worldwide.

Mary Glenn Vreeland, Senior Director, Evidence Project Management – United States, Worldwide Clinical Trials

With 25 years experience in the life sciences arena, Mary Glenn has extensive knowledge of real-world research, industry trends and emerging digital health technologies. She establishes excellent relationships with clients and stakeholders, working harmoniously to design studies that are innovative, maximize value and address the competitive landscape. Mary Glenn has significant experience leading teams and ensuring they have the necessary resources and support to deliver customized solutions of the highest quality successfully and efficiently and in compliance with respective regulations. Her study experience spans all phases of research and numerous therapeutic areas. Throughout her career, Mary Glenn has held a variety of senior management positions within contract research organizations. Most recently, she was responsible for providing executive oversight on a portfolio of studies at the forefront of research, including a virtual COVID-19 study and the initiation of an inclusive research trial to broaden the understanding of multiple sclerosis disease biology among specific minorities. Mary Glenn has a Master of Health Administration from Washington University School of Medicine.

Florence Barkats, CCO and Digital Health & Technology Advisor, Cisiv Ltd.

Florence has 20 years’ experience in health informatics and real-world technology and methodology. Prior to working at Cisiv, she was Head of Clinical Services at Philips, held leadership roles at GE Healthcare Digital, Johnson & Johnson and was Head of Research for a digital health technology start-up. Florence also holds an advisory role with the UK NHS on digital transformation programmes and policy. She has a BSc degree from Johns Hopkins University and an MBA from London Business School.

Dilesh Doshi, PharmD, Vice President, Global Health Economics and Outcomes Research, Acadia Pharmaceuticals

Dilesh is the Vice President of Global Health Economics & Outcomes Research (HEOR) at Acadia Pharmaceuticals. His team is responsible for generating real-world evidence to guide appropriate treatments for patients with neuropsychiatric illness as well as children with rare disorders. The Global HEOR team also prepares for health technology and value assessment reviews conducted by governmental and non-governmental agencies.

Prior to joining Acadia, Dilesh was at Johnson & Johnson for 19 years. During his tenure at Janssen (J&J), Dilesh held various leadership roles, including Head of Real-World Evidence for a rare disease franchise, Founding Head of Population Health, Director of Translation Science and Director of Health Economics. He also spent several years in customer-facing payer liaison roles. Dilesh started his career at SmithKline Beecham within their health economics and pricing group.

Dilesh received his Bachelor of Science degree in Chemistry from Central Connecticut State University and a Doctor of Pharmacy from the University of California, San Francisco. He completed a two year post graduate fellowship at Thomas Jefferson School of Population Health in Philadelphia, PA. With over 80 podium presentations and peer reviewed publications including book chapters, manuscripts and posters, he is nationally recognized as a subject-matter expert and regularly invited as a conference speaker. He is a peer reviewer for scientific journals and has held a Faculty appointment for health economics and real-world evidence at the University of California, San Diego School of Pharmacy since 2009.